Skip to content

Remote Myocardial Ischemic Preconditioning in Humans

Remote Myocardial Ischemic Preconditioning in Humans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00588042
Acronym
RemoteMIPH
Enrollment
156
Registered
2008-01-08
Start date
2007-10-31
Completion date
2009-06-30
Last updated
2019-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Ischemia

Keywords

Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease, Coronary Occlusion

Brief summary

Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.

Detailed description

Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. We will also test the hypotheses that IP diminishes the inflammatory response to PCI, and that higher baseline blood endothelial progenitor cell counts are predictive of a favorable response to IP. Aim 1: To evaluate whether remote ischemic preconditioning reduces the frequency of myonecrosis (troponin T≥0.03 ng/ml following PCI). Aim 2: To evaluate whether remote ischemic preconditioning reduces the inflammatory response to PCI (post PCI hsCRP level). Aim 3: To evaluate whether pre-procedure circulating endothelial progenitor cell counts correlate with the effect of remote ischemic preconditioning on myonecrosis. Background: Percutaneous coronary intervention (PCI) frequently results in ischemic myonecrosis. Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. Aims: The aims of the study are to assess in patients with coronary artery disease requiring PCI, whether remote IP reduces: 1) the frequency of myonecrosis; and 2) the inflammatory response to PCI; and 3) whether the effect of IP correlates with pre-procedure circulating endothelial progenitor cell counts. Methods: The study is a prospective, randomized trial to assess the efficacy of remote IP as adjunctive non-pharmacological therapy for PCI in patients with stable or unstable angina. Remote IP will be performed by 3 cycles of 3-minutes of arm ischemia alternating with 3- minutes of reperfusion of the arm immediately before PCI. Myonecrosis and inflammation will be detected by measuring serum troponin T and high sensitivity C-reactive protein, respectively. Blood EPC counts will also be measured before the procedure.

Interventions

Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes

3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients will be eligible for randomization if they meet the following criteria: 1. Age ≥ 18 years 2. Clinically indicated elective or urgent PCI

Exclusion criteria

* Patients will be ineligible for the study if one or more of the following conditions exist: 1. Pre-PCI Troponin T ≥ 0.03 2. Systemic hypotension (systolic \<90 mmHg) or cardiogenic shock 3. Presence of an arteriovenous fistula or lymphedema of either arm 4. Currently enrolled in other active cardiovascular investigational studies 5. Severe endocrine, hepatic, renal, disorders 6. Pregnancy or lactation 7. Inability to provide consent 8. Federal Medical Center inmates 9. Inability or unwillingness to provide informed consent

Design outcomes

Primary

MeasureTime frame
Post PCI myonecrosis measured as a maximum troponin T ≥0.0316 hours post PCI

Secondary

MeasureTime frame
Post PCI myonecrosis measured as an elevation in creatine kinase MB fraction (CK-MB> 1 X upper limit of normal)16 hours post procedure
Magnitude of ST segment elevation on an intracoronary electrocardiogram during balloon inflationDuring PCI procedure
Coronary perfusion measured as coronary flow reserve derived from TIMI frame countsDuring PCI
Blood high sensitivity C-reactive protein levelImmediately prePCI
Blood endothelial progenitor cell counts (EPC)Immediately prePCI

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026